Reminyl, Galantamine
Reminyl, Galantamine Newswire

Reminyl, Galantamine Newswire

Comprehensive Real-Time News Feed for Reminyl, Galantamine (generic).

Results 1 - 12 of 12 in Reminyl, Galantamine (generic)

  1. Cerespir Submits Special Protocol Assessment Request To FDA For A...Read the original story

    Tuesday Jun 30 | BioSpace

    CereSpirTM Incorporated, a company with a novel approach to treat neurodegenerative diseases by harnessing the innate immune system, today announced the company has submitted a Special Protocol Assessment request to the U.S. Food and Drug Administration to initiate detailed design discussions for a Phase 3 clinical study of CSP-1103 to test its ability to slow the Progression of Mild Cognitive Impairment due to Alzheimer's Disease . The SPA request includes the proposed Phase III study protocol, statistical analysis plans and briefing materials along with specific questions from CereSpir to facilitate a meaningful dialogue with the FDA on the proposed study design.

    Comment?

  2. More evidence needed for chronic fatigue diagnosis, treatmentsRead the original story w/Photo

    Wednesday Jun 17 | PhysOrg Weblog

    Criteria for diagnosing myalgic encephalomyelitis/chronic fatigue syndrome as well as treatment options are addressed in two systematic evidence reviews published in the June 16 issue of the Annals of Internal Medicine . Elizabeth Haney, M.D., from the Oregon Health & Science University and Providence Cancer Center in Portland, and colleagues reviewed methods to diagnose ME/CFS in adults.

    Comment?

  3. Upcoming Events: A Dosing Decision For BioMarin, Plus Roche To Get Alzheimer's DataRead the original story w/Photo

    May 23, 2015 | Seeking Alpha

    Welcome to your weekly digest of approaching regulatory and clinical readouts. Data from BioMarin's Phase II trial of the achondroplasia project BMN 111, expected this month or next, will allow the company to decide whether to test a higher dose.

    Comment?

  4. Antidementia drug treatment in dementia networks in Germany: use...Read the original story

    May 22, 2015 | BioMed Central

    German Center for Neurodegenerative Diseases , Research Group "Interventional Health Care Research", Site Rostock/ Greifswald, Ellernholzstr. 1-2, Greifswald D-17487, Germany Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, Ernst-Moritz-Arndt-University Greifswald, Ellernholzstrasse 1-2, Greifswald D-17487, Germany Background Dementia networks in Germany constitute a specialised setting for integrated dementia care and have shown benefits on relevant outcomes, including those of drug treatment.

    Comment?

  5. The influence of cholinesterase inhibitor therapy for dementia on...Read the original story

    Apr 27, 2015 | BioMed Central

    Division of Geriatric Medicine, Department of Medicine, University of Ottawa, The Ottawa Hospital, 1053 Carling Avenue, Ottawa K1Y 4E9, Ontario, Canada Department of Epidemiology & Community Medicine, University of Ottawa; Ottawa Hospital Research Institute; ICES uOttawa, The Ottawa Hospital, ASB1-003, 1053 Carling Avenue, Ottawa K1Y 4E9, Ontario, Canada Background Cholinesterase inhibitors are used to treat the symptoms of dementia and can theoretically cause bradycardia. Previous studies suggest that patients taking these medications have an increased risk of undergoing pacemaker insertion.

    Comment?

  6. Effective Drug Therapy for Alzheimer's Disease Remains ElusiveRead the original story

    Mar 13, 2015 | ASHP

    In the two years since the United States set a national goal of effectively preventing or treating Alzheimer's disease by 2025, no new therapies have been approved, and recent clinical trials of investigational drugs have proved disappointing. According to the Pharmaceutical Research and Manufacturers of America, about 83% of drugs that are tested in clinical trials never earn FDA approval.

    Comment?

  7. memantine, Namenda, Namenda XRRead the original story w/Photo

    Feb 24, 2015 | MedicineNet

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

    Comment?

  8. AB Science : Successful Completion Of Futility Test For Masitinib In Alzheimer's DiseaseRead the original story

    Feb 9, 2015 | BioSpace

    AB Science SA , a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors , today announced the successful completion of a futility analysis related to the masitinib phase 3 trial for the treatment of mild to moderate Alzheimer's disease. Based on these results, the Independent Data Safety Monitoring Committee has recommended the continuation of the study.

    Comment?

  9. Holy moly? Snowdrops, like these at Colesbourne Park, may be the medicinal herb cited by HomerRead the original story w/Photo

    Feb 5, 2015 | Oxford Times

    They may only be a few inches high, with tiny white flowers, but snowdrops cause great excitement in February. They welcome in spring, albeit early spring, and we can't wait to get among them in February.

    Comment?

  10. Pharmacological treatments for frontotemporal dementias: a systematic ...Read the original story

    Dec 29, 2014 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. The objective of this review is to summarize the current data on the pharmacological treatments for frontotemporal dementias from randomized controlled trials.

    Comment?

  11. ENTREVESTOR: P.E.I. firm gains traction with drugRead the original story w/Photo

    Dec 18, 2014 | The Chronicle Herald

    Denis Kay has been a scientist for a long time, but he's most thrilled by his current role working on a promising drug for Alzheimer's disease. Alzheimer's is an escalating problem in aging societies.

    Comment?

  12. Cholinergic Stimulation Enhances Bayesian Belief Updating in the Deployment of Spatial AttentionRead the original story

    Nov 23, 2014 | CiteULike

    The Journal of Neuroscience , Vol. 34, No. 47. , pp. 15735-15742, doi:10.1523/jneurosci.0091-14.2014 To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?